BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis

Pharma To Announce IRA-Mandated Final Price Soon

Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.

MUNICH, GERMANY - 5. July 2024: Bristol Myers Squibb logo sign of the biopharmaceutical company.
BMS raised its 2024 revenue guidance based on its Q2 performance • Source: Shutterstock

Now that Bristol Myers Squibb Company has the maximum fair price (MFP) in hand that Medicare intends to pay for Eliquis (apixaban) starting in 2026 under the drug price negotiation authority granted by the Inflation Reduction Act (IRA), CEO Chris Boerner said the company is “increasingly confident in our ability to navigate the impact of IRA on Eliquis.”

Key Takeaways

  • BMS is “increasingly confident” in its ability to manage through pricing for Eliquis under IRA-mandated Medicare negotiations now that the company has seen the price effective 2026.

Boerner said during Bristol’s second quarter earnings call on 26 July that the company will disclose more details about how...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains